TLX Chart, page-1504

Radiopharmaceutical TherapyQDOSE(R) Platform Partnership for Personalized Dosimetry in Radiopharmaceutical Therapy MELBOURNE, Australia and DRESDEN, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- TelixPharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it hasentered into an agreement to commercially partner the QDOSE(R) dosimetry softwareplatform with ABX-CRO Advanced Pharmaceutical Services Forschungsgesellschaft mbH(ABX-CRO), a full-service contract research organization (CRO) based in Dresden, and itsdevelopment partner, Stockholm-based Quantinm AB. QDOSE(R) is a validated, versatile software platform that enables reliable estimationof patient-specific dosimetry for both therapeutic and diagnostic radiopharmaceuticals.Telix intends to integrate the QDOSE(R) platform into its therapeutic radiopharmaceuticalprograms and clinical collaborations to enable the development of personalized treatmentregimens. Personalized radiopharmaceutical therapy administration based on individualpatient dosimetry has the potential to improve clinical outcomes by optimizing treatmentresponse while reducing effects on normal healthy organs and optimizing the use ofisotope supply chains. QDOSE(R) supports dosimetry calculations using planar imaging, tomographic imaging,single/multi time point imaging and hybrid combinations. QDOSE(R) incorporates additionaltools for attenuation and background correction. The QDOSE(R) platform will be integratedwith Telix's artificial intelligence (AI) products as an accessible tool for cliniciansand third-party commercial drug developers. QDOSE(R) has received 510(k) clearance fromthe United States Food and Drug Administration (FDA) and is Conformit? Europ?enne (CE)marked for clinical use within the European Union (EU). Dr Christian Behrenbruch, Managing Director and Group CEO of Telix said, "In nuclearmedicine, dosimetry analysis is used to calculate the absorbed dose of radiation receivedby different parts of the body. Rapid, reliable and personalized dosimetry is becoming anincreasingly important future direction of cancer care and regulatory authorities nowexpect to see dosimetry analysis. QDOSE(R) has an excellent performance track record andwe are committed to positioning QDOSE(R) as a new industry standard in dosimetryanalysis." The arms' length up-front transaction consideration is non-material. Telix will payundisclosed product royalties and fees on product sales. About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercializationof diagnostic and therapeutic radiopharmaceuticals and associated medical devices. Telixis headquartered in Melbourne, Australia, with international operations in the UnitedStates, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio ofclinical and commercial stage products that aims to address significant unmet medicalneeds in oncology and rare diseases. Telix is listed on the Australian SecuritiesExchange (ASX: TLX).